Literature DB >> 33724003

Anti-CD44-Conjugated Olive Oil Liquid Nanocapsules for Targeting Pancreatic Cancer Stem Cells.

Saúl A Navarro-Marchal1,2,3,4, Carmen Griñán-Lisón1,2,3, José-Manuel Entrena5,6, Gloria Ruiz-Alcalá1,2,3, María Tristán-Manzano7, Francisco Martin7, Ignacio Pérez-Victoria8, José Manuel Peula-García9,10, Juan Antonio Marchal1,2,3,11.   

Abstract

The latest trends in cancer research and nanomedicine focus on using nanocarriers to target cancer stem cells (CSCs). Specifically, lipid liquid nanocapsules are usually developed as nanocarriers for lipophilic drug delivery. Here, we developed olive oil liquid NCs (O2LNCs) functionalized by covalent coupling of an anti-CD44-fluorescein isothiocyanate antibody (αCD44). First, O2LNCs are formed by a core of olive oil surrounded by a shell containing phospholipids, a nonionic surfactant, and deoxycholic acid molecules. Then, O2LNCs were coated with an αCD44 antibody (αCD44-O2LNC). The optimization of an αCD44 coating procedure, a complete physicochemical characterization, as well as clear evidence of their efficacy in vitro and in vivo were demonstrated. Our results indicate the high targeted uptake of these αCD44-O2LNCs, and the increased antitumor efficacy (up to four times) of paclitaxel-loaded-αCD44-O2LNC compared to free paclitaxel in pancreatic CSCs (PCSCs). Also, αCD44-O2LNCs were able to selectively target PCSCs in an orthotopic xenotransplant in vivo model.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33724003     DOI: 10.1021/acs.biomac.0c01546

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  7 in total

Review 1.  Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy.

Authors:  Valentina Foglizzo; Serena Marchiò
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

2.  Physiological lentiviral vectors for the generation of improved CAR-T cells.

Authors:  María Tristán-Manzano; Noelia Maldonado-Pérez; Pedro Justicia-Lirio; Pilar Muñoz; Marina Cortijo-Gutiérrez; Kristina Pavlovic; Rosario Jiménez-Moreno; Sonia Nogueras; M Dolores Carmona; Sabina Sánchez-Hernández; Araceli Aguilar-González; María Castella; Manel Juan; Concepción Marañón; Juan Antonio Marchal; Karim Benabdellah; Concha Herrera; Francisco Martin
Journal:  Mol Ther Oncolytics       Date:  2022-05-18       Impact factor: 6.311

3.  Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles.

Authors:  José M Espejo-Román; Belén Rubio-Ruiz; Victoria Cano-Cortés; Olga Cruz-López; Saúl Gonzalez-Resines; Carmen Domene; Ana Conejo-García; Rosario M Sánchez-Martín
Journal:  Pharmaceutics       Date:  2022-04-04       Impact factor: 6.525

Review 4.  Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy.

Authors:  Wenhao Liao; Yuchen Li; Jing Wang; Maoyuan Zhao; Nianzhi Chen; Qiao Zheng; Lina Wan; Yu Mou; Jianyuan Tang; Zhilei Wang
Journal:  Int J Nanomedicine       Date:  2022-09-14

Review 5.  Targeting cancer stem cells with polymer nanoparticles for gastrointestinal cancer treatment.

Authors:  Yao Sun; Bo Li; Qian Cao; Tongjun Liu; Jiannan Li
Journal:  Stem Cell Res Ther       Date:  2022-10-01       Impact factor: 8.079

Review 6.  An Up-to-Date Review of Natural Nanoparticles for Cancer Management.

Authors:  Daniel Ion; Adelina-Gabriela Niculescu; Dan Nicolae Păduraru; Octavian Andronic; Florentina Mușat; Alexandru Mihai Grumezescu; Alexandra Bolocan
Journal:  Pharmaceutics       Date:  2021-12-22       Impact factor: 6.321

Review 7.  Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance.

Authors:  Michelle K Greene; Michael C Johnston; Christopher J Scott
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.